229 related articles for article (PubMed ID: 26411314)
1. Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes.
Egawa C; Hirokaga K; Takao S; Yamagami K; Miyashita M; Baba M; Ichii S; Konishi M; Kikawa Y; Minohata J; Okuno T; Miyauchi K; Wakita K; Suwa H; Hashimoto T; Nishino M; Matsumoto T; Hidaka T; Konishi Y; Sakoda Y; Miya A; Mitsunobu M; Nishikawa H; Kono S; Kokufu I; Sakita I; Kitatsuji K; Oh K; Miyoshi Y
Int J Clin Oncol; 2016 Apr; 21(2):262-269. PubMed ID: 26411314
[TBL] [Abstract][Full Text] [Related]
2. Body mass index and menopausal disorders during menopause affect vasomotor symptoms of postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes.
Tane K; Egawa C; Takao S; Yamagami K; Miyashita M; Baba M; Ichii S; Konishi M; Kikawa Y; Minohata J; Okuno T; Miyauchi K; Wakita K; Suwa H; Hashimoto T; Nishino M; Matsumoto T; Hidaka T; Konishi Y; Sakoda Y; Miya A; Kishimoto M; Nishikawa H; Kono S; Kokufu I; Sakita I; Kitatsuji K; Oh K; Akazawa K; Miyoshi Y
Breast Cancer; 2017 Jul; 24(4):528-534. PubMed ID: 27730528
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.
Sestak I; Cuzick J; Sapunar F; Eastell R; Forbes JF; Bianco AR; Buzdar AU;
Lancet Oncol; 2008 Sep; 9(9):866-72. PubMed ID: 18703382
[TBL] [Abstract][Full Text] [Related]
4. Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs).
Oberguggenberger A; Hubalek M; Sztankay M; Meraner V; Beer B; Oberacher H; Giesinger J; Kemmler G; Egle D; Gamper EM; Sperner-Unterweger B; Holzner B
Breast Cancer Res Treat; 2011 Jul; 128(2):553-61. PubMed ID: 21311968
[TBL] [Abstract][Full Text] [Related]
5. Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.
Prowell TM; Blackford AL; Byrne C; Khouri NF; Dowsett M; Folkerd E; Tarpinian KS; Powers PP; Wright LA; Donehower MG; Jeter SC; Armstrong DK; Emens LA; Fetting JH; Wolff AC; Garrett-Mayer E; Skaar TC; Davidson NE; Stearns V
Cancer Prev Res (Phila); 2011 Dec; 4(12):1993-2001. PubMed ID: 21885816
[TBL] [Abstract][Full Text] [Related]
6. Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy.
Pedersini R; Amoroso V; Maffezzoni F; Gallo F; Turla A; Monteverdi S; Ardine M; Ravanelli M; Vassalli L; Rodella F; Formenti AM; Dalla Volta A; Simoncini EL; Giustina A; Maroldi R; Berruti A
JAMA Netw Open; 2019 Sep; 2(9):e1911080. PubMed ID: 31560383
[TBL] [Abstract][Full Text] [Related]
7. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
[TBL] [Abstract][Full Text] [Related]
8. Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04).
Fontein DB; Charehbili A; Nortier JW; Putter H; Kranenbarg EM; Kroep JR; Linn SC; van de Velde CJ
Eur J Surg Oncol; 2017 Apr; 43(4):619-624. PubMed ID: 28017458
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609).
Lerebours F; Rivera S; Mouret-Reynier MA; Alran S; Venat-Bouvet L; Kerbrat P; Salmon R; Becette V; Bourgier C; Cherel P; Boussion V; Balleyguier C; Thibault F; Lavau-Denes S; Nabholz JM; Sigal B; Trassard M; Mathieu MC; Martin AL; Lemonnier J; Mouret-Fourme E
Cancer; 2016 Oct; 122(19):3032-40. PubMed ID: 27315583
[TBL] [Abstract][Full Text] [Related]
10. Incidence of joint symptoms and bone fractures in Japanese postmenopausal breast cancer patients treated with adjuvant anastrozole.
Okishiro M; Taguchi T; Kim SJ; Tanji Y; Shimazu K; Tamaki Y; Noguchi S
J Cancer Res Clin Oncol; 2009 Jun; 135(6):823-7. PubMed ID: 19034512
[TBL] [Abstract][Full Text] [Related]
11. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
Briot K; Tubiana-Hulin M; Bastit L; Kloos I; Roux C
Breast Cancer Res Treat; 2010 Feb; 120(1):127-34. PubMed ID: 20035381
[TBL] [Abstract][Full Text] [Related]
12. Joint symptoms and health-related quality of life in postmenopausal women with breast cancer who completed 5 years of anastrozole.
Yagata H; Ohtsu H; Komoike Y; Saji S; Takei H; Nakamura T; Ohashi Y; Iwase T; Shimozuma K
Support Care Cancer; 2016 Feb; 24(2):683-689. PubMed ID: 26153513
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Ganz PA; Cecchini RS; Julian TB; Margolese RG; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):857-65. PubMed ID: 26686960
[TBL] [Abstract][Full Text] [Related]
15. Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer.
Kadakia KC; Snyder CF; Kidwell KM; Seewald NJ; Flockhart DA; Skaar TC; Desta Z; Rae JM; Otte JL; Carpenter JS; Storniolo AM; Hayes DF; Stearns V; Henry NL
Oncologist; 2016 May; 21(5):539-46. PubMed ID: 27009936
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment?
Moscetti L; Agnese Fabbri M; Sperduti I; Fabrizio N; Frittelli P; Massari A; Pompei L; D'Auria G; Pofi E; Ruggeri EM
Tumori; 2015; 101(5):469-73. PubMed ID: 26108239
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04).
Takei H; Ohsumi S; Shimozuma K; Takehara M; Suemasu K; Ohashi Y; Hozumi Y
Breast Cancer Res Treat; 2012 May; 133(1):227-36. PubMed ID: 22234519
[TBL] [Abstract][Full Text] [Related]
18. Obesity and endocrine therapy: host factors and breast cancer outcome.
Goodwin PJ
Breast; 2013 Aug; 22 Suppl 2():S44-7. PubMed ID: 24074791
[TBL] [Abstract][Full Text] [Related]
19. Joint symptoms: a practical problem of anastrozole.
Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O; Sakamoto N
Breast Cancer; 2006; 13(3):284-288. PubMed ID: 16929123
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer.
Crew KD; Greenlee H; Capodice J; Raptis G; Brafman L; Fuentes D; Sierra A; Hershman DL
J Clin Oncol; 2007 Sep; 25(25):3877-83. PubMed ID: 17761973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
